search
Back to results

SL-AF Trial - (Six Lead Identification of Atrial Fibrillation [AF]) (SL-AF)

Primary Purpose

Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
RhythmPadGP
Sponsored by
Cardiocity Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Atrial Fibrillation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age greater or equal to 18 years of age
  • able to consent
  • attending to St Peter's Hospital for an ECG
  • No known allergies to the velcro or metal used in the RhythmPadGP leads

Exclusion Criteria:

  • Age less than 18 years of age
  • Not able to consent
  • Allergies to the metal/velcro strap
  • Medical condition affecting the wrists that may be interfered with by the attachment of the RhythmPdGP leads, such as a fractured limb that has a cast
  • Those with pacemakers or other implanted cardiac devices that would interfere with the ECG recording

Sites / Locations

  • Ashford and St Peters NHS Trust

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ECG acquisition

Arm Description

ECG acquisition using the standard ECG machine Intervention: An ECG will be performed on every participant using the novel device called the 'RhythmPadGP'

Outcomes

Primary Outcome Measures

Six Lead Identification of Atrial Fibrillation

Secondary Outcome Measures

Full Information

First Posted
March 24, 2015
Last Updated
August 9, 2016
Sponsor
Cardiocity Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT02401451
Brief Title
SL-AF Trial - (Six Lead Identification of Atrial Fibrillation [AF])
Acronym
SL-AF
Official Title
SL-AF Trial - (Six Lead Identification of Atrial Fibrillation [AF])
Study Type
Interventional

2. Study Status

Record Verification Date
August 2016
Overall Recruitment Status
Completed
Study Start Date
October 2014 (undefined)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cardiocity Limited

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The 12-lead ECG is an essential tool in cardiovascular assessment. Novel technology has the potential to improve the diagnostic yield of arrhythmias, whilst improving the patient experience. The RhythmPadGP is a novel device which acquires a 6-lead ECG without the need for the patient to undress. The aim of the study is to assess the ability of the device to diagnose cardiac rhythms. Simultaneous recording of the RhythmPadGP 6-lead ECG will be undertaken at the same time as the standard 12-lead ECG. The 12-lead ECGs and 6-lead ECGs will be analysed by a Cardiologist, who will be blinded to each set of ECGs and the automated diagnostic report produced by the RhythmPadGP device. Such a novel diagnostic tool could replace the standard 12-lead ECG for rapid assessment and diagnosis of arrhythmias. Additionally, as calls for a national screening programme to detect atrial fibrillation (and prevent AF-related thromboembolism) currently intensify, the RhythmPad has the potential to revolutionise how we screen our patients.
Detailed Description
The concept for the Rhythm Pad is to screen the public non-invasively for a cardiac rhythm abnormality, every time that they interact with a clinician. Cardiocity have conducted significant trialing of the RhythmPad product within both the primary care setting at the Old Cottage Hospital in Epsom and in a secondary care setting at St Peter's Hospital in Chertsey. The initial results were encouraging with a simple hand screening providing an indication of AF in 66% of the confirmed cases of AF, when verified by a traditional electrocardiogram (ECG) known as a GE MAC550 12 lead device as the benchmark. The main aim is for the RhythmPad range of products to increase the ability to diagnose cardiac rhythm abnormalities, along with reducing the number of false positive referrals to secondary care for a 12 lead Electrocardiogram of ECG. As such confirming the diagnosis before referral reduces the number of false positive referrals. If one of our algorithms thinks that there is evidence that the person might be in a state of Atrial Fibrillation (AF), Flutter, might have left or right bundle branch block, etc, then by moving to the 6 lead we are able to increase the confidence of the diagnosis. The RhythmPad is now able to support a 6 lead ECG acquisition, this is by using a modified device called the RhythmPadGP as such we would plan to trial this technology with St Peter's Hospital. We have learnt from the experiences of the previous trails. We know that 5% of the entire population will not have strong enough Lead 1 ECG when measured from their hands. Also those with Essential Tremor, Parkinson's etc. are not able to keep their hands steady for an accurate reading to be taken. In such cases, or as an escalation from the one lead data, we now offer through a simple Velcro ankle strap attachment the ability to record 6 leads of data.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
750 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ECG acquisition
Arm Type
Experimental
Arm Description
ECG acquisition using the standard ECG machine Intervention: An ECG will be performed on every participant using the novel device called the 'RhythmPadGP'
Intervention Type
Device
Intervention Name(s)
RhythmPadGP
Intervention Description
ECG acquisition using a novel device RhythmPadGP
Primary Outcome Measure Information:
Title
Six Lead Identification of Atrial Fibrillation
Time Frame
9 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age greater or equal to 18 years of age able to consent attending to St Peter's Hospital for an ECG No known allergies to the velcro or metal used in the RhythmPadGP leads Exclusion Criteria: Age less than 18 years of age Not able to consent Allergies to the metal/velcro strap Medical condition affecting the wrists that may be interfered with by the attachment of the RhythmPdGP leads, such as a fractured limb that has a cast Those with pacemakers or other implanted cardiac devices that would interfere with the ECG recording
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Riyaz A Kaba, MBBS
Organizational Affiliation
Ashford and St Peter's Hospitals NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ashford and St Peters NHS Trust
City
Surrey
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

SL-AF Trial - (Six Lead Identification of Atrial Fibrillation [AF])

We'll reach out to this number within 24 hrs